VBI Vaccines Inc


Prices are adjusted according to historical splits.

VBI Vaccines Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$25.85 million
Book Value:
Revenue TTM:
$1.82 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

VBI Vaccines Inc had its IPO on 1995-08-18 under the ticker symbol VBIV.

The company operates in the Healthcare sector and Biotechnology industry. VBI Vaccines Inc has a staff strength of 190 employees.

Stock update

Shares of VBI Vaccines Inc opened at $1.2 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.08 - $1.2, and closed at $1.11.

This is a -1.77% slip from the previous day's closing price.

A total volume of 243,058 shares were traded at the close of the day’s session.

In the last one week, shares of VBI Vaccines Inc have slipped by -10.48%.

VBI Vaccines Inc's Key Ratios

VBI Vaccines Inc has a market cap of $25.85 million, indicating a price to book ratio of 1.5634 and a price to sales ratio of 139.5181.

In the last 12-months VBI Vaccines Inc’s revenue was $1.82 million with a gross profit of $-10194000 and an EBITDA of $-77414000. The EBITDA ratio measures VBI Vaccines Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, VBI Vaccines Inc’s operating margin was -4378.95% while its return on assets stood at -38.14% with a return of equity of -207.76%.

In Q2, VBI Vaccines Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 108.1%.

VBI Vaccines Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-13.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into VBI Vaccines Inc’s profitability.

VBI Vaccines Inc stock is trading at a EV to sales ratio of 114.2447 and a EV to EBITDA ratio of -0.9516. Its price to sales ratio in the trailing 12-months stood at 139.5181.

VBI Vaccines Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$88.32 million
Total Liabilities
$27.67 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

VBI Vaccines Inc ended 2023 with $88.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $88.32 million while shareholder equity stood at $8.74 million.

VBI Vaccines Inc ended 2023 with $0 in deferred long-term liabilities, $27.67 million in other current liabilities, 442322000.00 in common stock, $-561988000.00 in retained earnings and $2.18 million in goodwill. Its cash balance stood at $20.84 million and cash and short-term investments were $20.84 million. The company’s total short-term debt was $2,983,000 while long-term debt stood at $47.84 million.

VBI Vaccines Inc’s total current assets stands at $31.89 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.66 million compared to accounts payable of $7.35 million and inventory worth $6.86 million.

In 2023, VBI Vaccines Inc's operating cash flow was $0 while its capital expenditure stood at $50000.

Comparatively, VBI Vaccines Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

VBI Vaccines Inc stock is currently trading at $1.11 per share. It touched a 52-week high of $25.497 and a 52-week low of $25.497. Analysts tracking the stock have a 12-month average target price of $4.

Its 50-day moving average was $1.33 and 200-day moving average was $7.54 The short ratio stood at 0.31 indicating a short percent outstanding of 0%.

Around 952% of the company’s stock are held by insiders while 1362.1% are held by institutions.

Frequently Asked Questions About VBI Vaccines Inc

The stock symbol (also called stock or share ticker) of VBI Vaccines Inc is VBIV

The IPO of VBI Vaccines Inc took place on 1995-08-18

Similar Industry Stocks (Biotechnology)

Last Price
Inhibrx Inc (INBX)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.


160 Second Street, Cambridge, MA, United States, 02142